Nuwellis (NUWE) Stock Price, News & Analysis

Company Overview

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Key Stats

• Today's Range: $5.11 to $5.66
• 50-Day Range: $4.96 to $16.93
• 52-Week Range: $4.82 to $175.98
• Volume: 341,919 shs
• Average Volume: 217,757 shs
• Market Capitalization: $564 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Nuwellis Stock Analysis - MarketRank™

Nuwellis scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Nuwellis.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nuwellis are expected to grow in the coming year, from ($8.17) to ($0.89) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nuwellis is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nuwellis is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nuwellis has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

76.90% of the float of Nuwellis has been sold short.

Short Interest Ratio / Days to Cover

Nuwellis has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nuwellis has recently decreased by 34.35%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuwellis does not currently pay a dividend.

Dividend Growth

Nuwellis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

76.90% of the float of Nuwellis has been sold short.

Short Interest Ratio / Days to Cover

Nuwellis has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nuwellis has recently decreased by 34.35%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: -0.01

News Sentiment

Nuwellis has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Nuwellis this week, compared to 1 article on an average week.

Search Interest

Only 7 people have searched for NUWE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Nuwellis to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nuwellis insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.08% of the stock of Nuwellis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 3.13% of the stock of Nuwellis is held by institutions.

NUWE Stock Analysis - Frequently Asked Questions

How have NUWE shares performed this year?

Nuwellis' stock was trading at $46.62 on January 1st, 2025. Since then, NUWE stock has decreased by 87.9% and is now trading at $5.64.

How were Nuwellis' earnings last quarter?

Nuwellis, Inc. (NASDAQ:NUWE) issued its earnings results on Tuesday, August, 12th. The company reported ($60.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $60.54. Nuwellis had a negative trailing twelve-month return on equity of 655.31% and a negative net margin of 112.09%.
Read the conference call transcript.

When did Nuwellis' stock split?

Shares of Nuwellis reverse split on Friday, June 28th 2024.The 1-35 reverse split was announced on Friday, June 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Nuwellis?

Shares of NUWE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nuwellis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuwellis investors own include Verb Technology (VERB), TransCode Therapeutics (RNAZ), Exela Technologies (XELA), AMC Entertainment (AMC), BIOLASE (BIOL) and Terran Orbital (LLAP).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NUWE
• CIK: 1506492
• Web: www.nuwellis.com
• Phone: (952) 345-4200
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($766.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.16 million
• Net Margins: -112.09%
• Pretax Margin: -112.04%
• Return on Equity: -655.31%
• Return on Assets: -141.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.23
• Quick Ratio: 1.59

Sales & Book Value

• Annual Sales: $8.79 million
• Price / Sales: 0.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $62.71 per share
• Price / Book: 0.08

Miscellaneous

• Outstanding Shares: 105,000
• Free Float: 84,000
• Market Cap: $552.20 thousand
• Optionable: Not Optionable
• Beta: N/A